🏛️ Verified NIH Record • Updated 2026-06-01
Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma (NCT00539591)
🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: St. Jude Children's Research Hospital
🩺 Plain-English Summary (8th-Grade Level)
The main goal of this study is to estimate the tumor response rate of temozolomide administered in combination with peginterferon alfa-2b to pediatric patients with unresectable Stage III, metastatic, or recurrent cutaneous melanoma.
Who can join: Review the eligibility criteria below.
Location: Rady Children's Hospital — San Diego, California
Age range: Not specified to 21 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (3 Sites)
- Rady Children's Hospital — San Diego, California
- St. Jude Children's Research Hospital — Memphis, Tennessee
- The Children's Cancer Hospital at UT M.D. Anderson Cancer Center — Houston, Texas
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Malignant Melanoma
Explore by condition: All Malignant Melanoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.